The usual intuition that a higher dose is at least a stronger version of the same thing is simply false here
doi:10.1177/2331216515580272 9
In the UK, several GLP-1 receptor agonists are licensed by the Medicines and Healthcare products Regulatory Agency (MHRA), each with specific indications: semaglutide (Ozempic for type 2 diabetes, Wegovy for weight management), dulaglutide (Trulicity for type 2 diabetes), and liraglutide (Victoza for type 2 diabetes, Saxenda for weight management)
While studies are currently exploring the possibilities of preventing these side effects, there are currently no GLP-1 drugs on the market that do not have the potential to cause these side effects
Certificate of Analysis Certificates of Analysis Janoshik Third-party tested Independent analytical lab Frequently Asked Questions The KLOW Blend combines four peptides: GHK-Cu, BPC-157, TB-500, and KPV